Global life sciences AI · Published 16 November 2026 · HERMS Consultancy DMCC
See how HERMS delivers integrated life sciences solutions.
A defensible cosmetics product dossier links the exact marketed formulation, intended use and claims to reliable ingredient information, an appropriate finished-product safety assessment and evidence supporting each claimed effect. Build one controlled evidence core, then add market-specific classification, ingredient, labeling, notification and reporting requirements. Safety evidence and efficacy evidence answer different questions; neither a supplier brochure nor a notification number proves both. The strongest dossier makes its assumptions, limitations, versions and accountable approvals clear enough for an independent reviewer to understand. Legislation — Cosmetics Technical document on cosmetic claims Modernization of Cosmetics Regulation Act of 2022 (MoCRA) Making cosmetic products available to consumers in Great Britain Regulatory overview of cosmetic products
Start with classification: what is the product allowed to claim?
Identify the product category in every target market before commissioning tests or finalizing advertising. Intended use is communicated through names, pack copy, images, websites, retailer listings and promotional materials—not only a formal regulatory description. The same formulation can raise different classification questions when the claims change.
FDA distinguishes cosmetics from drugs by intended use. Disease-treatment or prevention claims and certain structure/function claims can make a product a drug or a cosmetic/drug combination. US examples include antidandruff shampoos and some sun-protection products. “Cosmeceutical” is not a separate legal category under the US FD&C Act. Do not assume a global cosmetics dossier makes such a product compliant as an ordinary cosmetic everywhere. Is It a Cosmetic, a Drug, or Both? (Or Is It Soap?)
Create a classification memo for each market, identifying the exact claims and relevant authority resources. Where the boundary is uncertain, seek appropriate advice before treating a marketing phrase as harmless. Replacing one disease word does not necessarily change the overall intended-use message.
Separate safety substantiation from claims substantiation
Safety asks whether the product is safe under the relevant normal or reasonably foreseeable conditions of use. Claims substantiation asks whether a message about its performance or characteristics is adequately supported. A tolerability study does not demonstrate wrinkle reduction; a hydration result does not establish overall safety. Legislation — Cosmetics Technical document on cosmetic claims Modernization of Cosmetics Regulation Act of 2022 (MoCRA)
| Evidence question | Typical supporting material | What it does not automatically prove |
|---|---|---|
| Is the ingredient appropriate? | Identity, specifications, restrictions and toxicology | Finished-formula safety at every concentration or exposure |
| Is the finished product safe? | Formulation-specific assessment, quality and exposure information | Every advertised performance claim |
| Does the claimed effect occur? | Relevant instrumental, expert or consumer evidence | Global classification or regulatory compliance |
| Can the product be marketed here? | Local classification, labeling, responsible entity and required filings | Authority endorsement or universal acceptance |
| Is evidence still applicable? | Change assessment and post-market review | That an older test covers every new formulation or pack |
Maintain separate but linked safety and claims conclusions. Both should point to the same product identity, formulation version, use conditions and packaging where relevant. This prevents a frequent dossier weakness: sound reports that cannot be confidently connected to the product actually sold.
Build a global evidence core with local modules
A global dossier is a proposed document architecture, not one universally recognized legal submission. The EU/GB PIF, US safety substantiation records and ASEAN-aligned documentation have different legal roles. Reuse evidence where scientifically and legally appropriate, but do not relabel one market’s file as a complete global authorization. Legislation — Cosmetics Modernization of Cosmetics Regulation Act of 2022 (MoCRA) Making cosmetic products available to consumers in Great Britain Regulation 1223/2009 and the Cosmetic Products Enforcement Regulations 2013: Great Britain ASEAN Cosmetic Directive
| Core module | Key contents | Control point |
|---|---|---|
| Product identity | Names, SKUs, formula, specifications, manufacturer, use and packaging | Link every report to a controlled product version |
| Ingredient evidence | Identity, composition, purity, impurities, supplier data and restrictions | Verify actual supplied grade and conditions of use |
| Quality / manufacture | Method, GMP evidence, specifications and traceability | Confirm records apply to the manufacturing source |
| Finished-product safety | Exposure, toxicology synthesis, quality and relevant test information | Qualified assessment and justified limitations |
| Claims evidence | Exact wording, implied message, studies and permitted scope | Claim-to-evidence mapping and approval |
| Market modules | Classification, local entity, labeling, filings and reporting | Current jurisdiction/date check |
| Lifecycle records | Changes, complaints, undesirable effects and reassessments | Defined owner and review triggers |
Include an evidence-gap register. For each missing document or uncertainty, assign an owner, consequence and closure condition. A missing supplier annex and an unresolved serious safety concern should not be treated as equivalent administrative tasks.
Ingredient evidence: identity and context come before reputation
Record the INCI name and relevant chemical identifiers, supplied material composition, functional role, concentration in the finished formula and supplier/grade. Complex mixtures, extracts, fragrances and materials with carrier solvents need sufficient detail to understand actual exposure. An attractive ingredient story is not a toxicological specification.
Review purity, relevant impurities, contaminants, residuals, batch specifications and available toxicology. The required depth depends on material, use and risk. Confirm the local status of prohibited/restricted substances and permitted functions, such as preservatives, colourants or UV filters. An ingredient name appearing in an information database is not blanket approval for every use.
Date the legal review. The Commission’s cosmetics legislation index lists ongoing amendments, including 2026 changes; HSA’s ASEAN resource page identifies updated ingredient annexes. A prior launch or an unchanged supplier statement does not establish continuing compliance in every market. Verify applicable restrictions and transition provisions for the actual formulation. Legislation — Cosmetics ASEAN Cosmetic Directive
Safety assessment is exposure-driven and formulation-specific
Assess product type, amount, frequency, application site, leave-on/rinse-off use, target population and foreseeable exposure routes. Consider whether children, sensitive sites, sprays or other circumstances require particular attention. A general statement that an ingredient is widely used cannot replace assessment of its concentration and exposure in this product.
The SCCS Notes of Guidance describe exposure-driven evaluation, weight of evidence and developments in non-animal methodologies. They are scientific guidance, not an ingredient or finished-product marketing authorization. Their emphasis is ingredient assessment, and the approach must be adapted to the question rather than used as a mechanical checklist. SCCS Notes of guidance for the testing of cosmetic ingredients and their safety evaluation — 12th revision
In EU/GB-style safety documentation, distinguish the assembled safety information from the assessor’s reasoned conclusion, warnings and justification. The responsible entity needs an appropriately qualified assessor under the relevant framework. Neither a signed template with missing data nor an automated report establishes an adequate assessment. GB guidance explicitly requires safety to be checked by a qualified assessor before availability. Legislation — Cosmetics Making cosmetic products available to consumers in Great Britain Regulation 1223/2009 and the Cosmetic Products Enforcement Regulations 2013: Great Britain
Quality evidence: stability, microbiology and packaging matter
A formula’s safety and claimed performance depend on what remains in the container over its intended life. Define the relevant physicochemical specifications, stability questions, microbiological quality and packaging interactions. Consider use conditions, contamination opportunities and formulation characteristics when deciding which studies and assessments are appropriate.
Preservative efficacy testing and microbiological limits answer different questions. A brief absence of detected contamination is not proof that a water-containing product remains adequately protected during use. Conversely, do not prescribe one identical testing battery for every cosmetic; justify the program with the assessor and applicable requirements. FDA states that law and regulations do not mandate specific universal tests for each cosmetic, but require adequate safety substantiation. Modernization of Cosmetics Regulation Act of 2022 (MoCRA)
Assess changes to the pack, closure, dispensing mechanism or material-contact surfaces. A move from a pump to a jar can change use conditions even if the formula is identical. Record the scientific basis for bridging existing data or the need for additional evidence.
Claims substantiation: map every promise to the right evidence
The EU common criteria are legal compliance, truthfulness, evidential support, honesty, fairness and informed decision-making. They apply to the overall communicated message, not just isolated words. The supporting evidence should be consistent with what the consumer is likely to understand. Commission Regulation 655/2013 Technical document on cosmetic claims
| Proposed claim type | Suitable evidence question | Common overreach |
|---|---|---|
| Hydration / appearance benefit | Does an appropriate method support the stated effect and timing? | Turning a measured short-term result into a lasting universal promise |
| Visible wrinkle improvement | Does the design assess the intended appearance endpoint in relevant users? | Implying disease treatment or effects not measured |
| Consumer preference / perception | What did participants report, under which conditions? | Presenting subjective opinion as objective clinical measurement |
| Ingredient-based benefit | Does evidence justify extrapolation to this finished product? | Using supplier ingredient data as proof of product-level effect |
| Dermatologically tested | What was tested, by whom, with what findings? | Implying guaranteed tolerance or authority endorsement |
| Hypoallergenic / sensitive skin | Does the total evidence support the intended message? | Promising zero allergy risk or replacing safety assessment |
| Free-from / clean / natural | Is the message accurate, clear, relevant and non-misleading? | Implying lawful ingredients are unsafe or natural means safe |
These are examples for review, not pre-approved wording. EU technical guidance warns against unsupported extrapolation from ingredient properties to the finished product and addresses evidence for “hypoallergenic” and “free-from” claims. It is nonbinding guidance supporting interpretation, not a substitute for the law or case-specific authority decisions. Technical document on cosmetic claims
Design claim studies around the exact message
Prespecify the claim, population, product version, conditions, endpoints, timing and analysis. Use a comparator or control where appropriate to the question. Justify sample size and methods, handle missing data transparently and distinguish exploratory findings from prespecified conclusions.
Instrumental measurements, expert grading, consumer-perception testing and published evidence can support different messages. They are not interchangeable. A perception study may substantiate how participants felt or what they observed; it should not automatically be promoted to a quantified biological change. Technical document on cosmetic claims
Retain the complete report, including protocol, product identification, results, interpretation, relevant statistical methods and responsible sign-off. Do not select only favorable endpoints or the best photograph. Digital retouching, lighting and other presentation choices should not communicate an effect beyond the evidence. Claims and substantiation must be assessed together in their actual presentation. Commission Regulation 655/2013 Technical document on cosmetic claims
Create a claim-to-evidence register
Use a controlled register spanning packs, websites, marketplaces, social content and distributor materials. Capture the exact wording and any implied message, language, market, product version, source evidence, limitations, approval and review trigger.
| Register field | Why it matters |
|---|---|
| Exact claim and market | A small wording or translation change can alter the message |
| Product/formula/pack version | Evidence must apply to the product sold |
| Evidence and endpoint | Reviewers need to identify precisely what was demonstrated |
| Use conditions and limitations | Prevent broader timing, population or application promises |
| Approvers and date | Assign accountable scientific/regulatory review |
| Published locations | Find and correct inconsistent retailer or promotional claims |
| Change/review triggers | Keep evidence valid after reformulation, new data or legal change |
The register is a proposed governance tool, not a claim that one global template is legally mandatory. Test it by selecting a live claim and asking whether an independent reviewer can trace the statement to a relevant result and the marketed product.
Jurisdictional differences: one evidence core, different obligations
| Market | Selected requirements and distinctions | Dossier consequence |
|---|---|---|
| European Union | Responsible Person, safety assessment/report, PIF, CPNP and common claims criteria | Maintain product-linked safety/claims evidence and current ingredient/label review |
| Great Britain | GB Responsible Person, English PIF, qualified assessor and GB notification | Treat GB as a distinct module; Northern Ireland has a separate framework |
| United States | MoCRA safety-substantiation records and other applicable duties; classification by intended use | Do not assume EU CPSR format is the US legal requirement; evaluate exemptions and current implementing status |
| Singapore / ASEAN-aligned system | Local notification, ACD ingredient/label/claim standards and accessible technical evidence | Follow Singapore implementation; harmonization is not one ASEAN approval |
| Other markets, including GCC | Country/product-specific classification, documentation and filing review needed | No unverified universal GCC registration route is asserted |
MoCRA requires the responsible person to ensure and maintain adequate safety-substantiation records. Facility registration/product listing and other duties have applicable scope and exemptions; do not assume one exemption removes all safety responsibilities. FDA does not generally pre-approve ordinary cosmetics, except the applicable colour-additive requirements; product listing is not an FDA endorsement. Drug/cosmetic combinations face additional requirements. Modernization of Cosmetics Regulation Act of 2022 (MoCRA) Is It a Cosmetic, a Drug, or Both? (Or Is It Soap?)
In Singapore, HSA explicitly states that cosmetic notification is not product approval or certification of safety/quality. ASEAN alignment does not remove the dealer’s responsibilities or national implementation differences. In Great Britain, follow OPSS requirements rather than assuming EU CPNP notification alone covers GB. Making cosmetic products available to consumers in Great Britain Regulatory overview of cosmetic products ASEAN Cosmetic Directive Submit notification and re-notification
Post-market evidence keeps the dossier defensible
Collect and assess complaints, undesirable effects, serious cases, quality defects and relevant new scientific information. Link them to product and batch identity where possible. Define who evaluates seriousness, reporting obligations, investigation and corrective action in each market. EU rules include reporting of serious undesirable effects; MoCRA and Singapore have their own relevant requirements. Legislation — Cosmetics Modernization of Cosmetics Regulation Act of 2022 (MoCRA) Regulatory overview of cosmetic products
A small study without observed reactions cannot establish that reactions will never occur. Post-market patterns may change the safety assessment, warnings, claims or formulation. Preserve review decisions and ensure corrective communications reach the channels where the claim or product is actually available.
Reformulation and supplier changes need evidence impact assessment
Assess changes in ingredient concentration, grade, impurity profile, fragrance, manufacturing site, process, packaging, target users and use instructions. Review safety and claims separately: a change can leave one conclusion intact while undermining the other.
The technical claims document specifically notes that evidence should remain applicable when formulation changes. Document any bridging rationale rather than assuming “equivalent” materials have identical evidence. Update local filings and labels where required, with timing assessed under the relevant market rules. Technical document on cosmetic claims Making cosmetic products available to consumers in Great Britain Regulatory overview of cosmetic products
Hypothetical example: a moisturiser claim expands across markets
A company has an instrumental hydration study on a defined moisturiser formulation and proposes a broader campaign implying treatment of a skin disease. The team separates the demonstrated hydration endpoint from the proposed medicinal message and conducts a market-specific classification review before publication.
It also discovers a new fragrance supplier and different packaging for export. The safety assessor reviews the actual supplied material, exposure and pack implications; the claims reviewer assesses whether the existing study still applies. The company either narrows the message, obtains appropriate evidence or changes the regulatory plan. This is illustrative, not a HERMS case study or asserted test result.
A practical dossier-readiness checklist
- Classification is documented for each market and exact intended-use message.
- The marketed product, formula, supplier grades and packaging are controlled.
- Ingredient legality and restrictions are checked against current local sources.
- Exposure, quality and toxicology gaps have reasoned resolutions.
- The safety assessment/report is appropriate and approved by the required qualified role.
- Each material claim maps to applicable evidence, endpoint and conditions.
- Study reports identify the tested product and disclose limitations.
- Labels, translations, websites and retailer materials are consistent.
- Responsible entities, notifications/listings and required local records are addressed.
- Complaints, adverse/undesirable effects, changes and reassessment have named owners.
This checklist is a proposed review aid, not a universal statutory form. Readiness means that an unresolved concern cannot be hidden behind document volume or a notification acknowledgement.
HERMS perspective: connect claims, sources and accountable review
HERMS describes regulatory strategy, submission intelligence, scientific-claims review and evidence-integrity solution areas. These are company positioning statements, not independently established cosmetic safety-assessment capabilities, certifications or regulator acceptance. A relevant discussion should test source traceability, product-version linkage, local requirements and appropriate expert approvals. AI Life Sciences Software | 25 HERMS Solutions
Explore HERMS regulatory and evidence-integrity solutions to discuss a dossier-readiness or claims-evidence review workflow with appropriate specialist oversight.
Frequently asked questions
What is a cosmetics product dossier?
It is a structured set of product identity, safety, quality, claims and regulatory records. Its legally required format and contents differ by market. A global evidence core can improve consistency, but it does not replace a required local PIF, safety-substantiation record or notification process. Modernization of Cosmetics Regulation Act of 2022 (MoCRA) Making cosmetic products available to consumers in Great Britain ASEAN Cosmetic Directive
Is a PIF the same as a CPSR?
No. A Cosmetic Product Safety Report is a component of the Product Information File in the relevant framework. The PIF also contains product identity, manufacturing/GMP information and claim-related support, among other applicable material. Do not treat a safety report alone as the entire dossier. Making cosmetic products available to consumers in Great Britain Regulation 1223/2009 and the Cosmetic Products Enforcement Regulations 2013: Great Britain
Can ingredient studies support finished-product claims?
Sometimes, if extrapolation is scientifically justified and verifiable for the formulation, concentration, use and intended message. A supplier’s ingredient result is not automatically proof that the finished cosmetic delivers the same effect. Evaluate the weight and relevance of all available evidence. Technical document on cosmetic claims
Does MoCRA require a fixed safety-test battery?
FDA says neither the law nor its regulations specify universal tests for every individual cosmetic or ingredient. The responsible person must ensure and retain adequate safety substantiation supported by scientifically robust evidence. The appropriate assessment depends on the actual product and available information. Modernization of Cosmetics Regulation Act of 2022 (MoCRA)
Does notification mean regulatory approval?
No general assumption is justified. Singapore explicitly states its cosmetic notification is not endorsement or approval. EU/GB notification processes likewise should not be represented as independent proof of product efficacy. Maintain safety, quality and claims evidence regardless of a filing acknowledgement. Commission Regulation 655/2013 Making cosmetic products available to consumers in Great Britain Submit notification and re-notification
Does natural mean safe or hypoallergenic?
No. Origin alone does not establish safety or low allergenic potential. Evaluate actual composition, exposure and evidence. EU technical guidance addresses hypoallergenic claims and does not support a promise of zero allergy risk. Avoid messages that exceed the substantiation or mislead about lawful ingredients. Technical document on cosmetic claims SCCS Notes of guidance for the testing of cosmetic ingredients and their safety evaluation — 12th revision
Can sunscreen or anti-acne claims change classification?
Yes, depending on jurisdiction and the actual intended-use message. In the US, FDA identifies sun-protection and acne-treatment uses as drug-related categories, sometimes combined with cosmetic uses. Check the local framework rather than assuming a cosmetic classification follows the product worldwide. Is It a Cosmetic, a Drug, or Both? (Or Is It Soap?)
When should the dossier be updated?
When material formulation, supplier, packaging, use, claim, legal or safety information changes, and at appropriate review points. Reassess whether prior studies still apply, update local records as required and preserve the reasoned decision. A dossier is a maintained evidence system, not a one-time launch archive. Technical document on cosmetic claims Making cosmetic products available to consumers in Great Britain Regulatory overview of cosmetic products
A defensible cosmetics dossier does not merely contain documents. It demonstrates that the marketed product is the assessed product, that the advertised message matches the evidence and that local obligations and new safety information are actively managed.
Discuss evidence and dossier-readiness priorities through HERMS Solutions , or explore related HERMS regulatory and product-registration insights .
Relevant HERMS solutions
Explore RULEXIS regulatory strategy, KLYRA medical communications and claims review, and VERIQIS evidence integrity and assurance for the workflows discussed in this article.
Sources and further reading
- Legislation — Cosmetics
- Technical document on cosmetic claims
- Modernization of Cosmetics Regulation Act of 2022 (MoCRA)
- Making cosmetic products available to consumers in Great Britain
- Regulatory overview of cosmetic products
- Is It a Cosmetic, a Drug, or Both? (Or Is It Soap?)
- Regulation 1223/2009 and the Cosmetic Products Enforcement Regulations 2013: Great Britain
- ASEAN Cosmetic Directive
- SCCS Notes of guidance for the testing of cosmetic ingredients and their safety evaluation — 12th revision
- Commission Regulation 655/2013
- Submit notification and re-notification
Explore the pharmaceutical AI series
- AI decision authority and human oversight
- Agentic versus generative AI in pharmaceuticals
- AI governance in life sciences
- Human approval controls for pharmaceutical AI
- Real-world evidence for regulatory and market access
- AI medical device validation and change control
- Global pharmaceutical market access, HTA and pricing evidence
- Preparing healthcare data for AI
- AI pharmaceutical manufacturing and quality controls
Explore HERMS life sciences solutions and AI governance and traceability, or request a workflow-focused demonstration.
